Early progress on accelerating drug development with Claude

Anthropic's life sciences team is partnering with six organizations, including BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group, to accelerate drug development. They have also begun their own drug discovery efforts. Claude, their AI system, has proven useful in various stages of the drug development process, from identifying targets to designing molecules, optimizing them for manufacturing, drafting regulatory filings, and designing clinical trials.

These collaborations aim to identify and address bottlenecks throughout the drug development process. Generate Biomedicines is working on reengineering CAR T-cell therapy, a treatment for blood cell cancers, to treat solid tumor cancers. By shortening one part of the therapy's genetic instructions, they were able to create a design that was more effective in lab tests, allowing immune cells to make roughly 10 times as many receptors and killing tumor cells more efficiently.

Divergence Labs is developing drugs for food allergies by detaching IgE from immune cells entirely, rather than neutralizing IgE circulating in the blood. Claude helped generate around 35,000 antibody designs in about a month, with three designs able to bind to IgE and 20 able to dislodge it, with three of those appearing to dislodge IgE more effectively than standard medications.

BigHat Biosciences is optimizing leads for potential drugs through automated lab work. They used Claude to improve three properties of two leads, both antibody fragments targeting cancer cells and keeping drugs stable in the body: binding tightly, remaining stable, and avoiding clumping. Claude proposed changes to the molecules, and BigHat's scientists refined and tested them, resulting in the best versions binding over 10 times more tightly than the originals.